SHJ002
Phase 2Small molecule
SHJ002 is one of 21 small molecule programs targeting Myopia. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
58 competitors in Myopia
#DrugCompanyPhaseTrials
1Atropen
FFresenius Kabi Oncology Ltd.
Approved
Alphagan
NovartisApproved
Isopto Carpine
AAdvanz Pharma
Approved
Mitosol
UUroGen Pharma Ltd.
Approved
Oxylone
AbbVieApproved
Lucentis
RochePhase 3
Mydriacyl
FFalcon
Approved
Lotemax
PPharmos
Approved
Avastin
BBio-Thera Solutions
Phase 3
Carboxymethylcellulose
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHJ002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSunhawk Vision Biotech, Inc.